MX2010002005A - Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa. - Google Patents

Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.

Info

Publication number
MX2010002005A
MX2010002005A MX2010002005A MX2010002005A MX2010002005A MX 2010002005 A MX2010002005 A MX 2010002005A MX 2010002005 A MX2010002005 A MX 2010002005A MX 2010002005 A MX2010002005 A MX 2010002005A MX 2010002005 A MX2010002005 A MX 2010002005A
Authority
MX
Mexico
Prior art keywords
raf
compounds
kinase inhibitors
heteroarylamino
abl
Prior art date
Application number
MX2010002005A
Other languages
English (en)
Inventor
Juliet Nabakka
Xiaolin Li
Jon Loren
Donatella Chianelli
Valentina Molteni
Xiaodong Liu
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2010002005A publication Critical patent/MX2010002005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona compuestos de la fórmula (I): (ver fórmula I) y composiciones farmacéuticas de los mismos, los cuales son útiles como inhibidores de cinasa de proteína, así como métodos para utilizar tales compuestos con el fin de tratar, aminorar, o prevenir una condición asociada con una actividad de cinasa anormal o mal regulada. En algunas modalidades, la invención proporciona métodos para utilizar tales compuestos con el fin de tratar, aminorar, o prevenir enfermedades o trastornos que involucren una activación anormal de las cinasas c-kit, PDGFRa, PDGFRß, CSF1R, Abl, BCRAbl, CSK, JNK1, JNK2, p38, p70S6K, TGFß, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2ß, BRK, Fms, KDR, c-raf o b-raf.
MX2010002005A 2007-08-22 2008-08-18 Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa. MX2010002005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95724007P 2007-08-22 2007-08-22
PCT/US2008/073438 WO2009026204A1 (en) 2007-08-22 2008-08-18 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2010002005A true MX2010002005A (es) 2010-03-11

Family

ID=39930713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002005A MX2010002005A (es) 2007-08-22 2008-08-18 Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.

Country Status (13)

Country Link
US (1) US8288540B2 (es)
EP (1) EP2190836B1 (es)
JP (1) JP5303557B2 (es)
KR (1) KR101171488B1 (es)
CN (1) CN101784539A (es)
AT (1) ATE520682T1 (es)
AU (1) AU2008289135B2 (es)
BR (1) BRPI0815572A2 (es)
CA (1) CA2697077C (es)
EA (1) EA017392B1 (es)
ES (1) ES2368876T3 (es)
MX (1) MX2010002005A (es)
WO (1) WO2009026204A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155689B1 (en) 2007-05-31 2015-07-08 Boehringer Ingelheim International GmbH Ccr2 receptor antagonists and uses thereof
PT2190825E (pt) 2007-08-22 2014-07-16 Irm Llc Compostos e composições de 5-(4- (haloalcoxi)fenil)pirimidina-2-amina como inibidores de cinases
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
ES2524829T3 (es) 2009-12-17 2014-12-12 Boehringer Ingelheim International Gmbh Nuevos antagonistas del receptor CCR2 y usos de los mismos
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5647339B2 (ja) 2010-05-17 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２アンタゴニスト及びこれらの使用
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en) * 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
JP5889895B2 (ja) 2010-07-29 2016-03-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｍｐｋ活性化複素環化合物およびその使用方法
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
MX2014000963A (es) 2011-07-26 2014-03-27 Gruenenthal Gmbh Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
CN104458674A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种筛选血管内皮生长因子1激酶抑制剂高通量筛选方法
CN104458675A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种筛选干细胞因子受体激酶抑制剂高通量筛选方法
WO2015054574A1 (en) 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations
ES2778201T3 (es) 2013-11-21 2020-08-10 Brigham & Womens Hospital Inc Composiciones y métodos para tratar la hipertensión pulmonar
AU2015296037B2 (en) 2014-08-01 2021-04-29 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
JP6917910B2 (ja) 2015-07-02 2021-08-11 セントレクシオン セラピューティクス コーポレイション （４−（（３ｒ，４ｒ）−３−メトキシテトラヒドロ−ピラン−４−イルアミノ）ピペリジン−１−イル）（５−メチル−６−（（（２ｒ，６ｓ）−６−（ｐ−トリル）テトラヒドロ−２ｈ−ピラン−２−イル）メチルアミノ）ピリミジン−４イル）メタノンクエン酸塩
CA2994413A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Methods for treating myeloproliferative disorders
US9890163B2 (en) 2015-10-15 2018-02-13 Princeton Drug Discovery Inc Inhibitors of protein kinases
PL3481753T3 (pl) 2016-07-06 2021-07-19 Tomra Systems Asa Urządzenie i sposób do rozdzielania zużytych pojemników po napojach albo żywności
WO2018081567A1 (en) 2016-10-27 2018-05-03 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
HRP20230706T1 (hr) 2017-05-04 2023-10-13 Acceleron Pharma Inc. Fuzijski proteini tgf-beta receptora tipa ii i njihove upotrebe
US11130762B2 (en) 2017-05-24 2021-09-28 Abbisko Therapeutics Co., Ltd. Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164204A1 (en) 1984-05-12 1985-12-11 FISONS plc Novel pharmaceutically useful pyrimidines
CA2148931A1 (en) 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
WO2000035133A1 (en) * 1998-12-08 2000-06-15 Globespan Inc. Alternative configurations for an adsl system operating in a time duplex noise environment
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
EP1395261B1 (en) * 2001-05-16 2006-06-28 GPC Biotech AG Pyridylpyrimidine derivatives as effective compounds against prion diseases
US6958340B2 (en) * 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7117491B2 (en) * 2002-08-29 2006-10-03 International Business Machines Corporation Method, system, and program for determining whether data has been modified
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
EP1786799B1 (en) 2004-09-09 2012-07-04 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
BRPI0516597A (pt) * 2004-10-13 2008-09-16 Wyeth Corp composto da fórmula
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
AU2005325676A1 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CN101155799A (zh) * 2005-03-16 2008-04-02 塔格根公司 嘧啶化合物和使用方法
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
NZ566862A (en) * 2005-09-27 2010-12-24 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of C-kit receptors
CA2628474A1 (en) * 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
EP2079729A1 (en) 2006-11-03 2009-07-22 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0811617A2 (pt) 2007-05-04 2017-06-06 Irm Llc derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.
EA019524B1 (ru) 2007-05-04 2014-04-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR
PT2190825E (pt) 2007-08-22 2014-07-16 Irm Llc Compostos e composições de 5-(4- (haloalcoxi)fenil)pirimidina-2-amina como inibidores de cinases

Also Published As

Publication number Publication date
EP2190836A1 (en) 2010-06-02
KR101171488B1 (ko) 2012-08-07
US20110053952A1 (en) 2011-03-03
BRPI0815572A2 (pt) 2015-02-18
ATE520682T1 (de) 2011-09-15
JP2010536865A (ja) 2010-12-02
ES2368876T3 (es) 2011-11-23
CA2697077C (en) 2012-10-16
EA017392B1 (ru) 2012-12-28
EP2190836B1 (en) 2011-08-17
US8288540B2 (en) 2012-10-16
AU2008289135B2 (en) 2012-02-23
EA201000325A1 (ru) 2010-10-29
WO2009026204A1 (en) 2009-02-26
CA2697077A1 (en) 2009-02-26
KR20100050554A (ko) 2010-05-13
CN101784539A (zh) 2010-07-21
AU2008289135A1 (en) 2009-02-26
JP5303557B2 (ja) 2013-10-02

Similar Documents

Publication Publication Date Title
MX2010002005A (es) Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
MX2009004141A (es) Composiciones y metodos para modular receptores de c-kit y pdgfr.
TN2010000087A1 (en) 5-(4- haloalkoxy) phenyl pyrimidine -2- aminecompounds and compositons as kinase inhibitors
TNSN06406A1 (en) Compounds and compositions as protein kinase inhibitors
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
MX2009003456A (es) Compuestos y composiciones como inhibidores de proteina cinasa.
WO2005034869A3 (en) Compounds and compositions as protein kinase inhibitors
MX2008002165A (es) Compuestos y composiciones como inhibidores de la proteina cinasa.
PT2027123E (pt) Compostos e composi??es como inibidores da prote?na quinase
MX2009013782A (es) Inhibidores de cinasa de proteina y metodos para el uso de los mismos.
EA201000003A1 (ru) Ингибиторы протеинкиназ и способы их применения
MX2008001969A (es) Compuestos y composiciones como inhibidores de proteina cinasa.
TN2014000068A1 (en) Compounds and compositions as c-kit kinase inhibitors
TN2014000061A1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2005039486A3 (en) Compounds and compositions as protein kinase inhibitors
WO2005030151A3 (en) Compounds and compositions as protein kinase inhibitors
TH98294A (th) องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์
DOP2009000083A (es) Composiciones y metodos para modular recpetores de pdgfr y c-kit
TH98294B (th) องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์

Legal Events

Date Code Title Description
FG Grant or registration